NRX Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NRx Pharmaceuticals reports strong Q1 performance and growth opportunities

NRx Pharmaceuticals made strides in innovation, debt reduction, and financial stability in Q1 2024.
The company's focus on mental health treatments and addressing unmet medical needs shows market relevance.
Challenges include resolving short interest concerns and securing FDA approvals for key drugs.
Opportunities lie in out-licensing, revenue generation, and partnerships for growth and market expansion.

NRx Pharmaceuticals reports progress in financials and scientific breakthroughs

NRx Pharmaceuticals showcased financial and scientific progress, positioning itself for growth and market penetration.
Strategic initiatives like clinic roll-up and commercial targeting demonstrate a proactive approach to market challenges.
While facing transitions and competition, NRx Pharmaceuticals has opportunities for expansion and innovation in psychiatric treatments.
The company's focus on financial stability, product development, and market strategies reflects a comprehensive growth strategy.

NRx Pharmaceuticals reports improved financials and plans for growth

NRx Pharmaceuticals demonstrated improved financial performance and strategic planning in Q3 2024, with reduced losses and enhanced operational efficiency.
The company's focus on innovation, acquisitions, and precision psychiatry clinics highlights a commitment to growth and market leadership.
While facing challenges in revenue recognition and clinic valuations, NRx Pharmaceuticals has opportunities to drive revenue growth and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rx Pharmaceuticals Inc (NASDAQ: NRXP) shares are up around 25% during mid-day session on mild volume, in reaction to safety update on Zyesami (aviptadil) ACTIV-3 Critical Care Phase 3 study in COVID-19 patients. The NIH-sponsored trial's Data Safety Monitoring Board found no new safety concerns and recommended continued enrollment.

Why NRx Pharma Stock Is Trading Higher In Mid Day Session Wednesday?

RADNOR, Pa., Aug. 18, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health.

NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

NRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q2 2021 Results - Earnings Call Transcript

RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021.

NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

--Company to Host Conference Call August 17, 2021 at 8:30AM ET-- RADNOR, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second quarter 2021 financial results after the market close on August 16, 2021. The company will host a conference call and webcast on August 17, 2021, 8:30 AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Analysts and investors interested in submitting questions must do so in advance of the call and are encouraged to email questions to the Company's investor relations representative at jmullaly@lifesciadvisors.com.

NRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021

RADNOR, Pa., Aug. 10, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of NRx, will ring the Nasdaq Closing Bell on Tuesday, August 10, 2021 in celebration of NRx's listing on the Nasdaq Exchange.

NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has initiated a phase 2b dose-confirmatory trial of the BriLife vaccine against COVID-19 in the Nation of Georgia.  The vaccine is developed by the Israel Institute for Biological Research (IIBR).

NRx Pharma Starts Mid-Stage COVID-19 Vaccine Trial In Nation of Georgia

RADNOR, Pa., Aug. 9, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLife™ vaccine against COVID-19 in the Nation of Georgia.

NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia

MannKind

RADNOR, Pa., Aug. 4, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP), produced by the body to help protect cells against inflammatory conditions.

NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions

WESTLAKE VILLAGE, Calif., Aug. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) has partnered with NRx Pharmaceuticals (Nasdaq: NRXP) (NRx) to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP) – an endogenous substance produced by the body that helps protect cells against inflammatory conditions.

MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform

The Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for NRx Pharmaceuticals Inc's (NASDAQ: NRXP) intravenous Zyesami (aviptadil) to treat critical COVID-19 patients. The company says that the first doses will arrive in the Nation of Georgia within 24 hours.

NRx Pharma Stock Gains On Emergency Use Nod For Zyesami To Treat COVID-19 Patients In Nation Of Georgia

RADNOR, Pa., July 27, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage, global biopharmaceutical company, today announced that the Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous ZYESAMI™ (aviptadil) for the treatment of Critical COVID-19.

NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia

After soaring for a couple of days this popular COVID-19 stock fell back.

Here's Why NRx Pharmaceuticals Stock Dropped Monday

NRX Pharmaceuticals Inc. (NASDAQ: NRXP) shares rallied higher Friday on continued momentum after the company announced the first successful commercial formulation for Zyesami. The stock was trending on social media sites such as StockTwits Friday.

NRX Pharmaceuticals Climbs Higher After FDA News, Could See A Breakout Soon

The stock price of NRX Pharmaceuticals Inc (NASDAQ: NRXP) increased by over 25% pre-market. This is why it happened.

NRXP Stock Increases Over 25% Pre-Market: Why It Happened

Extending yesterday's gain, NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock is up more than 26% during the premarket trading on Friday. NRx's stock opened Thursday up nearly 14% at $11.51 per share after closing Wednesday at $10.11 per share.

Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?

The stock price of NRX Pharmaceuticals Inc (NASDAQ: NRXP) increased by 42.86% after hours. This is why it happened.

NRXP Stock Increased 42.86% After Hours: Why It Happened

NRXP stock came to investors' attention last year with its Covid-19 treatment. Now, it's looking like a great play as it eyes up EUA.

NRXP Stock: This Covid-19 Treatment Could Prime NRx Pharmaceuticals for Big Gains

The stock price of NRx Pharmaceuticals Inc (NASDAQ: NRXP) increased by over 80% during intraday trading. This is why it happened.

NRXP Stock Increased Over 80% Intraday: Why It Happened

The company achieved two breakthroughs related to the formulation and manufacturing of Zyesami, its experimental COVID-19 drug.

Why NRx Pharmaceuticals Stock Is Soaring Today

RADNOR, Pa., July 22, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has validated the first commercial formulation of ZYESAMI™ (aviptadil) for intravenous use, allowing for high volume manufacture, with an anticipated one year or greater stability, under appropriate storage conditions.

NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval

Shares of NRXP stock are taking off on Monday after the pharmaceutical company reported positive results regarding its Zyesami trial. The post NRXP Stock: The ‘Cykotine Storm' Drug News Sending NRx Pharma Shares Soaring appeared first on InvestorPlace.

NRXP Stock: The ‘Cykotine Storm' Drug News Sending NRx Pharma Shares Soaring

GT Biopharma Inc

IVERIC bio Inc

Penny Stocks & Small Caps Jump As Biotech Industry Names Kick Into High Gear The post Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech

The stock price of NRX Pharmaceuticals Inc (NASDAQ: NRXP) increased by over 30% during intraday trading. This is why it happened.

NRXP Stock Increases Over 30% Intraday: Why It Happened

NRx Pharmaceuticals (NASDAQ: NRXP) identifies a statistically significant effect of Zyesami (aviptadil) in preventing the sharp rise in cytokines, commonly associated with mortality in patients with COVID-19. Data will be presented at the Disease Control and Prevention Summit on July 21 at 10:10 E.T.

News for NRX Pharmaceuticals Stock (NRXP)